BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37315698)

  • 1. Development of VER-50589 analogs as novel Hsp90 inhibitors.
    Fang X; Feng J; Wang K; Luan Y
    Bioorg Med Chem Lett; 2023 Jul; 91():129375. PubMed ID: 37315698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors.
    Bizarro A; Sousa D; Lima RT; Musso L; Cincinelli R; Zuco V; De Cesare M; Dallavalle S; Vasconcelos MH
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29438315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues.
    Sharp SY; Prodromou C; Boxall K; Powers MV; Holmes JL; Box G; Matthews TP; Cheung KM; Kalusa A; James K; Hayes A; Hardcastle A; Dymock B; Brough PA; Barril X; Cansfield JE; Wright L; Surgenor A; Foloppe N; Hubbard RE; Aherne W; Pearl L; Jones K; McDonald E; Raynaud F; Eccles S; Drysdale M; Workman P
    Mol Cancer Ther; 2007 Apr; 6(4):1198-211. PubMed ID: 17431102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
    Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
    Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.
    Taniguchi H; Hasegawa H; Sasaki D; Ando K; Sawayama Y; Imanishi D; Taguchi J; Imaizumi Y; Hata T; Tsukasaki K; Uno N; Morinaga Y; Yanagihara K; Miyazaki Y
    Cancer Sci; 2014 Dec; 105(12):1601-8. PubMed ID: 25263741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
    El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
    Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
    Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
    Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
    Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
    Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.
    Montoir D; Barillé-Nion S; Tonnerre A; Juin P; Duflos M; Bazin MA
    Eur J Med Chem; 2016 Aug; 119():17-33. PubMed ID: 27153346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel heat shock protein (Hsp90) inhibitors based on luminespib with potent antitumor activity.
    Jung J; Kwon J; Hong S; Moon AN; Jeong J; Kwon S; Kim JA; Lee M; Lee H; Lee JH; Lee J
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127165. PubMed ID: 32305165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways.
    Xue N; Jin J; Liu D; Yan R; Zhang S; Yu X; Chen X
    Curr Cancer Drug Targets; 2014; 14(7):671-83. PubMed ID: 25219422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of New Hsp90 Inhibitors: Structure Based Virtual Screening, Molecular Dynamic Simulation, Synthesis and Biological Evaluation.
    Abbasi M; Amanlou M; Aghaei M; Hassanzadeh F; Sadeghi-Aliabadi H
    Anticancer Agents Med Chem; 2021; 21(18):2583-2591. PubMed ID: 33563187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agents.
    Zhang Y; Zhang TJ; Li XY; Liang JW; Tu S; Xu HL; Xue WH; Qian XH; Zhang ZH; Zhang X; Meng FH
    Eur J Med Chem; 2021 Jan; 210():112988. PubMed ID: 33189438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer.
    Nguyen CT; Thanh La M; Ann J; Nam G; Park HJ; Min Park J; Kim YJ; Young Kim J; Hong Seo J; Lee J
    Bioorg Med Chem Lett; 2021 Aug; 45():128134. PubMed ID: 34044120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and pharmacological evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides as potent Hsp90 inhibitors.
    Liang C; Wu X; Li Z; Zhu J; Lu C; Shen Y
    Eur J Med Chem; 2018 Jan; 143():85-96. PubMed ID: 29172085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
    Huang W; Ye M; Zhang LR; Wu QD; Zhang M; Xu JH; Zheng W
    Mol Cancer; 2014 Jun; 13():150. PubMed ID: 24927996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel matrinic acid derivatives bearing 2-anilinothiazole structure for non-small cell lung cancer treatment with improved Hsp90 targeting effect.
    Xu Y; Zeng P; Wang H; Han K; Qiu G; Wei Y; Chen R; Wang L; Liu X
    Drug Dev Res; 2022 Sep; 83(6):1434-1454. PubMed ID: 35841121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and molecular mechanisms of novel dual inhibitors of heat shock protein 90/phosphoinositide 3-kinase alpha (Hsp90/PI3Kα) against cutaneous melanoma.
    Qin F; Wang Y; Jiang X; Wang Y; Zhang N; Wen X; Wang L; Jiang Q; He G
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):909-926. PubMed ID: 30957641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-NSCLC activity in vitro of Hsp90
    Li HJ; Wang QS; Han W; Zhou H; Li P; Zhou F; Qin W; Zhao D; Zhou X; He CX; Xing L; Li PQ; Jin X; Yu F; He JH; Cao HL
    J Struct Biol; 2021 Jun; 213(2):107710. PubMed ID: 33610655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.